Oncogenic transformation of lung cells results in distinct exosome protein profile similar to the cell of origin. Issue 23 (15th September 2017)

• Record Type: Journal Article
• Authors: Lobb, Richard J.; Hastie, Marcus L.; Norris, Emma L.; van Amerongen, Rosa; Gorman, Jeffrey J.; Möller, Andreas
• Other Names: Mathivanan Suresh guestEditor.
• Is Part Of: Proteomics. Volume 17:Issue 23/24(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-09-15
• Subjects: diagnostic -- EGFR -- exosomes -- non‐small cell lung cancer; Proteins -- Separation -- Periodicals; Bioinformatics -- Periodicals; Proteomics -- Periodicals; Genomes -- Periodicals; Molecular genetics -- Periodicals; 572.605
• DOI: 10.1002/pmic.201600432
• Languages: English
• ISSNs: 1615-9853

Abstract

Abstract: Lung cancer is responsible for the highest rate of cancer mortality worldwide. Lung cancer patients are often ineligible for tumor biopsies due to comorbidities. As a result, patients may not have the most effective treatment regimens administered. Patients with mutations in the epidermal growth factor receptor (EGFR) have improved survival in response to EGFR tyrosine kinase inhibitors. A noninvasive method of determining EGFR mutations in patients would have promising clinical applications. Exosomes have the potential to be noninvasive novel diagnostic markers in cancer. Using MS analysis, we identify differentially abundant cell and exosome proteins induced by mutations in p53 and EGFR in lung cells. Importantly, mutations in p53 and EGFR alter cell and exosome protein content compared to an isogenic normal lung epithelial cell. For some proteins, mutation had similar effects in the cell of origin and exosomes. Differences between the cells of origin and exosomes were also apparent, which may reflect specific packaging of proteins into exosomes. These findings that mutations alter protein abundance in exosomes suggest that analysis of exosomes may be beneficial in the diagnosis of oncogenic mutations.